A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779
Completed
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2021
Locations: Southern Cancer Center, Mobile, Alabama +21 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
NCT03567616
Terminated
This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM) who received at least 1 prior line of therapy with documented evidence of progression during or after the participant's last treatment regimen. The study was designed to consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2021
Locations: John B. Amos Cancer Center - C /ID# 202055, Columbus, Georgia +10 locations
Conditions: Multiple Myeloma
Register for Updates
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
NCT02128230
Terminated
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2021
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
NCT02216071
Completed
The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension (Ciprodex®, Alcon) in the treatment of acute otitis externa (AOE) when administered twice daily for 7 days.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
05/27/2021
Locations: Birmingham Pediatric Associates, Birmingham, Alabama +47 locations
Conditions: Acute Otitis Externa
Register for Updates
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
NCT00151203
Completed
PRIMARY STUDY OBJECTIVES * To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). * To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES * To examine the role of clarithromycin on the pharmacokinetic properties of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2021
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Multiple Myeloma
Register for Updates
FST-201 In The Treatment of Acute Fungal Otitis Externa
NCT00945646
Terminated
The objective of this study is to evaluate the efficacy of FST-201 compared to vehicle in the treatment of acute fungal otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute fungal otitis externa.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2021
Locations: ENT Associates of South Florida, Boynton Beach, Florida +5 locations
Conditions: Acute Fungal Otitis Externa
Register for Updates
FST-201 In The Treatment of Acute Otitis Externa
NCT00945802
Terminated
The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2021
Locations: ENT Associates of South Florida, Boynton Beach, Florida +5 locations
Conditions: Acute Otitis Externa
Register for Updates
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
NCT04290676
Completed
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2021
Locations: Eye Center South Locations, Dothan, Alabama +21 locations
Conditions: Cataract
Register for Updates
Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section
NCT03098420
Terminated
The study aims to improve the care of the obstetric population after cesarean section and improve total patient satisfaction by improving post-surgical pain control with the use of dexamethasone in combination with bilateral TAP blocks. The investigators will utilize a dose-escalation of dexamethasone in the TAP block to observe its effects at specific small doses. It is the hope of the investigator that the studied technique would become utilized routinely for the obstetric population following... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2021
Locations: UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama
Conditions: Post Surgical Pain
Register for Updates
Dexamethasone Solution for the Treatment of Oral Lichen Planus
NCT02850601
Completed
The objective of this single center, 4-week, open label randomized, phase II study is to evaluate and characterize the tolerability and clinical effectiveness of dexamethasone 0.5mg/5ml solution in a mucoadhesive vehicle (Mucolox™) for the treatment of oral lichen planus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2021
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Lichen Planus
Register for Updates
Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
NCT02716818
Completed
This study is a parallel arm, randomised, open-label study, including dose titration and admissions for four overnight stays for 24-hour endocrine profiles. It will compare the efficacy, safety and tolerability of Chronocort® with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia (CAH) over a treatment period of 6 months. Dose titration decisions in both treatment groups will be made by a central independent physician, blinded to the treatment arm, us... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2021
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Congenital Adrenal Hyperplasia
Register for Updates
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT00538733
Completed
Study Objectives 1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). 2. Evaluate the efficacy of the addition of thalidomide (Thalomid®) to BiRD combination therapy as a therapy to increase the complete response rate for patients with newly diagnosed multiple myeloma. 3. Evaluate the safety of the combination of cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2021
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Multiple Myeloma
Register for Updates